vs
Emergent BioSolutions Inc.（EBS）与Ranger Energy Services, Inc.（RNGR）财务数据对比。点击上方公司名可切换其他公司
Emergent BioSolutions Inc.的季度营收约是Ranger Energy Services, Inc.的1.0倍（$148.7M vs $142.2M），Ranger Energy Services, Inc.净利率更高（2.3% vs -36.7%，领先39.0%），Ranger Energy Services, Inc.同比增速更快（-0.6% vs -23.6%），Emergent BioSolutions Inc.自由现金流更多（$73.8M vs $17.1M），过去两年Ranger Energy Services, Inc.的营收复合增速更高（1.9% vs -29.6%）
Emergent BioSolutions是一家总部位于美国马里兰州盖瑟斯堡的跨国专业生物制药企业，公司专注于开发针对传染病及阿片类药物过量的疫苗与抗体疗法，同时还为生物防御领域提供相关医疗设备支持。
Ranger Energy Services是北美领先的陆上油田服务提供商，为上游油气运营商提供完井、修井、钻机作业及产能优化等全套解决方案，业务主要覆盖美国本土的页岩和致密资源开采作业区。
EBS vs RNGR — 直观对比
营收规模更大
EBS
是对方的1.0倍
$142.2M
营收增速更快
RNGR
高出23.0%
-23.6%
净利率更高
RNGR
高出39.0%
-36.7%
自由现金流更多
EBS
多$56.7M
$17.1M
两年增速更快
RNGR
近两年复合增速
-29.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.7M | $142.2M |
| 净利润 | $-54.6M | $3.2M |
| 毛利率 | 42.9% | — |
| 营业利润率 | -18.8% | 2.3% |
| 净利率 | -36.7% | 2.3% |
| 营收同比 | -23.6% | -0.6% |
| 净利润同比 | -74.4% | -44.8% |
| 每股收益（稀释后） | $-0.95 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBSRNGR
| Q4 25 | $148.7M | $142.2M | ||
| Q3 25 | $231.1M | $128.9M | ||
| Q2 25 | $140.9M | $140.6M | ||
| Q1 25 | $222.2M | $135.2M | ||
| Q4 24 | $194.7M | $143.1M | ||
| Q3 24 | $293.8M | $153.0M | ||
| Q2 24 | $254.7M | $138.1M | ||
| Q1 24 | $300.4M | $136.9M |
净利润EBSRNGR
| Q4 25 | $-54.6M | $3.2M | ||
| Q3 25 | $51.2M | $1.2M | ||
| Q2 25 | $-12.0M | $7.3M | ||
| Q1 25 | $68.0M | $600.0K | ||
| Q4 24 | $-31.3M | $5.8M | ||
| Q3 24 | $114.8M | $8.7M | ||
| Q2 24 | $-283.1M | $4.7M | ||
| Q1 24 | $9.0M | $-800.0K |
毛利率EBSRNGR
| Q4 25 | 42.9% | — | ||
| Q3 25 | 62.8% | — | ||
| Q2 25 | 52.5% | — | ||
| Q1 25 | 60.2% | — | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | -18.8% | — | ||
| Q1 24 | 49.2% | — |
营业利润率EBSRNGR
| Q4 25 | -18.8% | 2.3% | ||
| Q3 25 | 33.1% | 2.0% | ||
| Q2 25 | 1.1% | 6.1% | ||
| Q1 25 | 22.5% | 0.7% | ||
| Q4 24 | -4.9% | 6.2% | ||
| Q3 24 | 22.0% | 8.4% | ||
| Q2 24 | -79.9% | 5.3% | ||
| Q1 24 | 13.2% | -0.4% |
净利率EBSRNGR
| Q4 25 | -36.7% | 2.3% | ||
| Q3 25 | 22.2% | 0.9% | ||
| Q2 25 | -8.5% | 5.2% | ||
| Q1 25 | 30.6% | 0.4% | ||
| Q4 24 | -16.1% | 4.1% | ||
| Q3 24 | 39.1% | 5.7% | ||
| Q2 24 | -111.2% | 3.4% | ||
| Q1 24 | 3.0% | -0.6% |
每股收益（稀释后）EBSRNGR
| Q4 25 | $-0.95 | $0.14 | ||
| Q3 25 | $0.91 | $0.05 | ||
| Q2 25 | $-0.22 | $0.32 | ||
| Q1 25 | $1.19 | $0.03 | ||
| Q4 24 | $-0.45 | $0.24 | ||
| Q3 24 | $2.06 | $0.39 | ||
| Q2 24 | $-5.38 | $0.21 | ||
| Q1 24 | $0.17 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $205.4M | $10.3M |
| 总债务越低越好 | $589.7M | — |
| 股东权益账面价值 | $522.6M | $300.1M |
| 总资产 | $1.3B | $419.3M |
| 负债/权益比越低杠杆越低 | 1.13× | — |
8季度趋势，按日历期对齐
现金及短期投资EBSRNGR
| Q4 25 | $205.4M | $10.3M | ||
| Q3 25 | $245.5M | $45.2M | ||
| Q2 25 | $267.3M | $48.9M | ||
| Q1 25 | $149.1M | $40.3M | ||
| Q4 24 | $99.5M | $40.9M | ||
| Q3 24 | $149.9M | $14.8M | ||
| Q2 24 | $69.7M | $8.7M | ||
| Q1 24 | $78.5M | $11.1M |
总债务EBSRNGR
| Q4 25 | $589.7M | — | ||
| Q3 25 | $693.1M | — | ||
| Q2 25 | $700.0M | — | ||
| Q1 25 | $700.0M | — | ||
| Q4 24 | $700.0M | $0 | ||
| Q3 24 | $700.8M | $0 | ||
| Q2 24 | $863.8M | $0 | ||
| Q1 24 | $909.2M | $0 |
股东权益EBSRNGR
| Q4 25 | $522.6M | $300.1M | ||
| Q3 25 | $582.5M | $270.0M | ||
| Q2 25 | $536.2M | $276.9M | ||
| Q1 25 | $552.7M | $272.6M | ||
| Q4 24 | $482.8M | $273.8M | ||
| Q3 24 | $508.4M | $267.6M | ||
| Q2 24 | $386.3M | $260.5M | ||
| Q1 24 | $663.9M | $261.7M |
总资产EBSRNGR
| Q4 25 | $1.3B | $419.3M | ||
| Q3 25 | $1.5B | $372.8M | ||
| Q2 25 | $1.4B | $381.7M | ||
| Q1 25 | $1.4B | $376.5M | ||
| Q4 24 | $1.4B | $381.6M | ||
| Q3 24 | $1.5B | $373.9M | ||
| Q2 24 | $1.5B | $359.6M | ||
| Q1 24 | $1.8B | $355.5M |
负债/权益比EBSRNGR
| Q4 25 | 1.13× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | 1.45× | 0.00× | ||
| Q3 24 | 1.38× | 0.00× | ||
| Q2 24 | 2.24× | 0.00× | ||
| Q1 24 | 1.37× | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.7M | $24.1M |
| 自由现金流经营现金流 - 资本支出 | $73.8M | $17.1M |
| 自由现金流率自由现金流/营收 | 49.6% | 12.0% |
| 资本支出强度资本支出/营收 | 2.6% | 4.9% |
| 现金转化率经营现金流/净利润 | — | 7.53× |
| 过去12个月自由现金流最近4个季度 | $156.8M | $42.9M |
8季度趋势，按日历期对齐
经营现金流EBSRNGR
| Q4 25 | $77.7M | $24.1M | ||
| Q3 25 | $-2.3M | $13.6M | ||
| Q2 25 | $106.4M | $20.7M | ||
| Q1 25 | $-11.2M | $10.6M | ||
| Q4 24 | $-79.9M | $32.7M | ||
| Q3 24 | $153.7M | $17.7M | ||
| Q2 24 | $47.5M | $22.1M | ||
| Q1 24 | $-62.6M | $12.0M |
自由现金流EBSRNGR
| Q4 25 | $73.8M | $17.1M | ||
| Q3 25 | $-5.7M | $8.0M | ||
| Q2 25 | $103.5M | $14.4M | ||
| Q1 25 | $-14.8M | $3.4M | ||
| Q4 24 | $-81.6M | $27.3M | ||
| Q3 24 | $147.9M | $10.8M | ||
| Q2 24 | $42.9M | $6.8M | ||
| Q1 24 | $-73.4M | $5.5M |
自由现金流率EBSRNGR
| Q4 25 | 49.6% | 12.0% | ||
| Q3 25 | -2.5% | 6.2% | ||
| Q2 25 | 73.5% | 10.2% | ||
| Q1 25 | -6.7% | 2.5% | ||
| Q4 24 | -41.9% | 19.1% | ||
| Q3 24 | 50.3% | 7.1% | ||
| Q2 24 | 16.8% | 4.9% | ||
| Q1 24 | -24.4% | 4.0% |
资本支出强度EBSRNGR
| Q4 25 | 2.6% | 4.9% | ||
| Q3 25 | 1.5% | 4.3% | ||
| Q2 25 | 2.1% | 4.5% | ||
| Q1 25 | 1.6% | 5.3% | ||
| Q4 24 | 0.9% | 3.8% | ||
| Q3 24 | 2.0% | 4.5% | ||
| Q2 24 | 1.8% | 11.1% | ||
| Q1 24 | 3.6% | 4.7% |
现金转化率EBSRNGR
| Q4 25 | — | 7.53× | ||
| Q3 25 | -0.04× | 11.33× | ||
| Q2 25 | — | 2.84× | ||
| Q1 25 | -0.16× | 17.67× | ||
| Q4 24 | — | 5.64× | ||
| Q3 24 | 1.34× | 2.03× | ||
| Q2 24 | — | 4.70× | ||
| Q1 24 | -6.96× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
RNGR
| High Specification Rigs | $92.3M | 65% |
| Processing Solutions And Ancillary Services | $37.5M | 26% |
| Wireline Services | $12.4M | 9% |
